Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT03405142
Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer
Overview
This phase 2 trial studies how well panitumumab-IRDye800 works in identifying head and neck cancer that has spread to the lymph nodes in patients with head and neck cancer. Panitumumab-IRDye800 may help surgeons to identify metastatic lymph nodes during surgical removal of the primary tumor and/or lymph nodes of the neck with equal or better accuracy than the current methods.
Sponsor
Stanford University
Phase
Phase 2
Contacts
Fred M Baik (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT03405142Drug / Compound
tilmanocept
Isotope(s):
TECHNETIUM-99m
Radioisotope: Tc-99m
Theranostic Role: SPECT Imaging
T1/2 (Half-Life): 6 Hours
Decay Mode: GAMMA
Energy: 140 keV (89.1%)
Range: N/A
Decay Daughters: Tc99
Status: FDA Approval: First in 1980’s
Target(s):
- Mannose Receptor (CD206/MRC1)
Ligand Class: Small Molecules
Chelator: DTPA
Eligibility
Inclusion
- Platelet count ≥ 100,000/mm³
- Cohort 2 (neck dissection only): Diagnosis with any T-stage, any subsite within the head and neck that are scheduled to undergo surgical resection, including a (modified) neck dissection
- White blood cell count \> 3000/mm³
- Patients with recurrent disease or a new primary will be allowed
- Biopsy-confirmed diagnosis of squamous cell carcinoma of the head and neck
- Have acceptable hematologic status, coagulation status, kidney function, and liver function including the following clinical results:
- Planned standard of care surgery with curative intent for squamous cell carcinoma
- Serum creatinine ≤ 1.5 times upper reference range
- Cohort 1: T1-T2 stage tumor diagnosis, any subsite within the head and neck that is amenable to local sentinel node tracer injection, and scheduled to undergo surgical resection of the tumor, including a sentinel node biopsy
- Hemoglobin ≥ 9 gm/dL
- Karnofsky performance status of at least 70% or ECOG/Zubrod level 1
Exclusion
- History or evidence of interstitial pneumonitis or pulmonary fibrosis
- Receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
- Magnesium or potassium lower than the normal institutional values
Share your feedback
Help us improve your experience